Going on the offensive against one of the most daunting challenges in cancer, The Leukemia & Lymphoma Society (LLS) today announced the launch of a groundbreaking, collaborative clinical trial for acute myeloid leukemia (AML), a deadly disease which has seen few improvements in treatments in more than 40 years.
Beat AML was announced yesterday by Vice President Biden, along with many new, Moonshot inspired initiatives across industry, non-profit and government.
AML is the most lethal of the blood cancers, which together are the third leading cause of cancer deaths in the U.S.; AML is responsible for more than 10,000 deaths each year. Despite advances in treating other blood cancers, the standard of treatment for AML – a combination of toxic chemotherapies – has remained the same for more than 40 years. Overall prognosis remains poor, with a five-year survival rate below 20 percent for patients over age 60.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554854-lls-beat-aml-acute-myeloid-leukemia/
Nearly 12 million men in the U.S. suffer from symptoms related to benign prostatic hyperplasia (BPH), an enlargement of the prostate that can cause issues such as frequent and weak urinary streams and sleep deprivation from getting up repeatedly during the night to urinate. Since traditional BPH therapies such as daily medications and more invasive or surgical procedures often result in unwanted side effects and complications, more than 54 percent of men who would benefit from treating their BPH choose not to do anything1. With today’s national introduction of the FDA-cleared Rezūm® System, NxThera provides urologists and their patients suffering from symptomatic BPH with a new, safe and effective minimally-invasive, office-based treatment option which improves quality of life and preserves sexual function2 – one of the main reasons many men choose to forego medications or more invasive procedures.
“Men suffering from BPH are constantly evaluating the trade-offs between maintaining their current declined quality of life or treating their BPH symptoms and possibly incurring long term side effects,” said Dr. Kia Michel, M.D., a urologist at Comprehensive Urology in Los Angeles who recently performed the procedure as part of a nationally televised segment on prostate health. “Of all the minimally-invasive BPH treatments I’ve performed, Rezūm is the most effective and most versatile treatment available to patients – and the results have been excellent.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7933151-nxthera-rezum-therapy/
University of St. Augustine for Health Sciences (USAHS), a leading graduate institution that emphasizes health and rehabilitative sciences education through innovative classroom education, is pleased to announce the installation of SafeGait 360° Balance and Mobility Trainer® on its Austin, Texas campus. The device, which was designed in collaboration with experts in physical therapy (PT) and occupational therapy (OT), works to mitigate the risk of injury from falls, protecting both the patient and therapist. In addition, SafeGait 360°’s dynamic fall protection (DFP) distinguishes between a patient’s intentional downward movement and when a patient is actually falling, which allows therapists to easily modify fall protection sensitivity to accommodate and challenge patients at varying stages of independence.
USAHS is one of the first higher education institutions in the nation to install this innovative body-weight support and fall protection system. In addition to conducting ground breaking research with patients and students, faculty members with extensive experience in body-weight treatments aim to open a clinic which will provide new treatment options to patients in the Austin community, and will begin seeing patients in October of this year.
To view the multimedia release go to:
http://www.multivu.com/players/English/7743851-usahs-safegait-360-physical-therapy/
Sickle cell disease (SCD) is an inherited, lifelong chronic disorder affecting nearly 100,000 Americans and a growing global health problem that will touch nearly 30 percent more people globally in the next three decades. Though new approaches to managing SCD have led to improvements in diagnosis and supportive care, people living with the disease still have severe complications to overcome. Many are unable to access quality care and are limited by a lack of effective treatment options.
In an effort to identify unmet medical needs for people with SCD, the American Society of Hematology (ASH), along with other groups, issued the State of Sickle Cell Disease: 2016 Report, evaluating the disease in four priority areas — access to care, training and professional education, research and clinical trials, and global health. The report shows that significant improvements are needed across all areas and that, though patients are living longer, the system of care needs to change to ensure a better quality of life. To address these challenges, ASH launched the Sickle Cell Disease Coalition along with more than 20 other organizations who are issuing a call to action that will amplify the voice of the SCD community, promote SCD awareness, and transform SCD care both in the United States and around the globe.
To view the multimedia release go to:
http://www.multivu.com/players/English/7903251-american-society-hematology-sickle-cell-coalition/
Team In Training. Light The Night. Man & Woman of the Year. Student Series. Leukemia Cup Regatta. More than 13 million participants in these popular fundraising campaigns last year alone helped The Leukemia & Lymphoma Society (LLS) invest more than $1 billion in research to advance lifesaving treatments and cures for blood cancer patients.
For Blood Cancer Awareness Month this September, LLS is reminding us that despite progress, much work still needs to be done to save more lives. More than 1.2 million people in the U.S. are living with or in remission from a blood cancer. Leukemia causes more deaths than any other cancer among children, adolescents and adults younger than 20 years. Leukemia, lymphoma and myeloma are expected to cause the deaths of an estimated 58,320 people in the U.S. in 2016.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554853-lls-blood-cancer-awareness-month/
Northwestern Medicine’s Bluhm Cardiovascular Institute is celebrating the success of its transcatheter valve program, a pioneering technology that replaces or repairs leaky heart valves without open-heart surgery. On August 25, 2016, more than 50 former transcatheter valve replacement patients and their family members celebrated the life-saving procedure that has extended both their lives and their ability to enjoy them.
The Bluhm Cardiovascular Institute hit the milestone of being the first hospital in Illinois to perform the 500th TAVR, or transcatheter aortic valve replacement, since the program’s inception in 2008. Charles J. Davidson, MD, performed the 500th procedure on July 23, 2016.
To view the multimedia release go to:
http://www.multivu.com/players/English/7049452-northwestern-medicine-transcatheter-valve/
Seqirus is now shipping its complete portfolio of seasonal influenza vaccines to customers in the US market for the 2016-2017 season. Seqirus is the only influenza vaccine manufacturer to produce influenza vaccines using both egg-based and cell culture technologies, and the only provider in the US that offers both quadrivalent and trivalent influenza vaccines, as well as the only adjuvanted seasonal influenza vaccine.
Seqirus is now shipping to the US all influenza vaccines in its portfolio, including Fluad™ (Influenza Vaccine, Adjuvanted), Flucelvax Quadrivalent™ (Influenza Vaccine), Afluria® (Influenza Vaccine), and Fluvirin® (Influenza Virus Vaccine) in advance of the peak of influenza season.
“Seqirus is proud to be a major contributor to the prevention and control of influenza by offering healthcare providers and pharmacists with a range of clinically proven, innovative vaccination options that help protect people against the debilitating effects of the disease,” said Brent MacGregor, Senior Vice President, Commercial Operations. “We are committed to being an early and reliable supplier of our influenza vaccines to help ensure that appropriate patients have plenty of time to get their annual immunization.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7902351-seqirus-franchise-shipment/
Soy consumption is up 14 percent since 2011,26 yet confusion lingers over soy’s role in everything from human health to food production. To clear up misperceptions, the United Soybean Board (USB) busts five common soy myths with science-backed facts on SoyConnection.com/soy-wisdom.
1) Eating soy does not increase breast cancer risk.
Clinical studies show soy isoflavone exposure does not adversely affect breast tissue as assessed by markers of breast cancer risk, such as breast cell proliferation.1–7 The American Institute for Cancer Research and the American Cancer Society say that women who have been diagnosed with breast cancer can safely consume soyfoods. In fact, the World Cancer Research Fund International has identified a link between soy consumption and an improved survival of breast cancer patients.8-9
“Not only does evidence indicate soyfoods may benefit women with breast cancer, but consuming soy when young helps prevent the onset of this disease later in life27-30,” stated Mark Messina, Ph.D., who has dedicated the past 30 years to understanding the health effects of soyfoods.
To view the multimedia release go to:
http://www.multivu.com/players/English/7877951-united-soybean-board-top-soy-myths/
The website www.MyPerfectDish.eu aims to help people with Parkinson’s, their relatives and caregivers in taking care of their nutritional requirements in order to help them enjoy tasty food that meets their dietary needs.
The website is endorsed by the European Parkinson’s Disease Association (EPDA) and sponsored by Zambon, and has been designed as an easy-to-use scientific information tool so people living with Parkinson’s can be confident that what they are reading is reliable.
“As the only European Parkinson’s umbrella organisation, the EPDA is very proud to endorse this project, which is based on solid scientific and medical grounds,” explains EPDA president Knut-Johan Onarheim. “A balanced and varied diet is important for everyone but it is even more important for people living with Parkinson’s disease because the right food intake can improve their quality of life as well as the effects of therapeutic treatments”.
“Zambon is very proud of having supported this project, which will help people with Parkinson’s and all those involved in the management of the disease. We are strongly committed to drive research and develop solutions to help patients in all their needs“. states Elena Zambon, President of Zambon.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7864251-parkinsons-diet-online-resource/
Solta Medical's novel addition to its aesthetic device solutions, the Clear + Brilliant pélo™ laser, offers personalized results with groundbreaking laser hair removal [LHR] technology to make it fast and simple with minimal pain for anyone to get rid of unwanted hair.
The Clear + Brilliant pélo™ laser provides a highly effective treatment in a short amount of time due to its innovative linear scanning technology and the largest treatment window in the market. A full back takes only 8-12 minutes, and full legs take about 36 minutes. After 5-6 treatments, patients can see the results they want, and still have money in their pocket for the long run.
Each treatment can be customized depending on the individual's needs, and patient comfort is enhanced by minimizing pain on contact through a sapphire glass handpiece that quickly chills to 0°C. So patients and physicians can rest easy that their individual needs are met.
To view the multimedia release go to:
http://www.multivu.com/players/English/7621831-clear-brilliant-pelo-laser-hair-removal/
A new survey from the Gout & Uric Acid Education Society (GUAES) finds many Americans with gout may be placing too much emphasis on diet when it comes to managing the disease and controlling painful flares. Of all the steps taken to manage gout, respondents cited changing their diet by eliminating or reducing consumption of certain foods as their top step taken (50 percent)—even ahead of taking medications to lower their uric acid levels (40 percent) and maintaining an overall healthy fitness level (33 percent). Furthermore, nearly one in three with gout incorrectly believes that the disease can be completely avoided by eliminating certain foods; and more than one in four said they would not take medications if they were making dietary changes.
“Physicians all too often see patients who believe they can successfully manage their gout with diet alone,” said N. Lawrence Edwards, M.D., a rheumatologist and GUAES chairman. “But even with extremely rigid diet restrictions, most gout patients will only be able to lower their uric acid levels slightly—not nearly enough to achieve a healthy level to control flares and reduce risk for long-term damage.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7835451-guaes-diet-survey/
Children who have disabilities will be able to express their unique experiences like never before thanks to a first-of-its-kind app developed by Gillette Children’s Specialty Healthcare in St. Paul, Minnesota.
The app, an ability-themed emoji keyboard called Emojability, will allow families, patients, caregivers and advocates in the special needs community to communicate, support one another and feel empowered to celebrate the goals and successes they’ve achieved. From adaptive equipment and therapy emojis to words of encouragement, Emojability brings to life symbols and phrases that don’t exist on other emoji keyboards. The free app is now available for download on smartphones.
To view the multimedia release go to:
http://www.multivu.com/players/English/7823251-gillette-childrens-emojability/
